AriaVax

AriaVax is a clinical-stage biotechnology company focused on the development of novel biologics and vaccines for the prevention of infectious diseases, with a primary specialization in malaria. Headquartered in Rockville, Maryland, the company was founded to commercialize advanced research from the National Institutes of Health (NIH), specifically targeting the circumsporozoite protein (CSP) of the malaria parasite. AriaVax's lead programs involve highly potent monoclonal antibodies, such as CIS43LS and L9LS, which are designed to provide long-term seasonal protection against malaria infection through passive immunization. The company operates as a sister entity to Sanaria Inc., leveraging a shared mission and leadership to provide a comprehensive suite of tools for malaria eradication. By focusing on subunit-based approaches, AriaVax complements whole-parasite vaccine strategies with scalable, antibody-based interventions.